56
Participants
Start Date
April 30, 2008
Primary Completion Date
May 31, 2011
Study Completion Date
May 31, 2011
Panobinostat
Participants received escalating doses of panobinostat until the maximum tolerated dose (MTD) was reached. The starting dose of panobinostat i.v. was 10mg/m\^2 at days 1 and 8 during a 21-day treatment cycle. The oral panobinostat starting dose was 20 mg twice weekly.
Trastuzumab
Fixed doses of trastuzumab were given in parallel with panobinostat. Trastuzumab i.v. was given weekly according to the instruction in the package insert.
University of Pittsburgh Cancer Institute Dept of Magee Women's Hospital, Pittsburgh
Novartis Investigative Site, Genova
Novartis Investigative Site, Dijon
VA Maryland Health Care Dept.of GreenbaumCancerCent(3), Baltimore
Novartis Investigative Site, Modena
Ohio State Comprehensive Cancer Center/James Cancer Hospital SC, Columbus
Novartis Investigative Site, Saint-Herblain Cédex
Novartis Investigative Site, Meldola
The Center for Cancer Care and Research, St Louis
Novartis Investigative Site, Heidelberg
Novartis Investigative Site, Paris
University of Colorado Dept. of Univ. of Colorado, Aurora
University of California at Los Angeles, Los Angeles
Norwalk Hospital Dept of Norwalk Hospital (2), Norwalk
Novartis Investigative Site, Kelowna
Novartis Investigative Site, Toronto
Novartis Investigative Site, Montreal
Novartis Investigative Site, Birmingham
Novartis Investigative Site, London
Novartis Investigative Site, Manchester
Lead Sponsor
Novartis Pharmaceuticals
INDUSTRY